In a bid to extend its leadership in oncology, Genentech has partnered with Bicycle Therapeutics to discover, develop and commercialise immuno-oncology therapies based on the latter’s bicyclic peptide (Bicycle®) technology. According to a company source, Bicycles possess pharmacological properties normally associated with a biologic but with the manufacturing and pharmacokinetic advantages of a small molecule. With no signs of immunogenicity observed to date, the technology has already been validated by the likes of AstraZeneca and Sanofi’s Bioverativ in indications beyond oncology.